Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0370 +0.0006 (+1.65%)
Streaming Delayed Price Updated: 1:29 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 58,500
Open 0.0365
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0364
Today's Range 0.0364 - 0.0377
52wk Range 0.0150 - 0.1100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AINewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In Editorial On AI-Driven Transformation of Pharmaceutical Manufacturing
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
Via Investor Brand Network
Topics Artificial Intelligence

Performance

YTD
-52.4%
-52.4%
1 Month
-12.3%
-12.3%
3 Month
-56.5%
-56.5%
6 Month
-58.8%
-58.8%
1 Year
-36.1%
-36.1%

More News

Read More
AINewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in AINewsWire Editorial on AI-Driven Pharma Compliance
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
From AINewsWire
Via GlobeNewswire
From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research
Via Investor Brand Network
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
From AINewsWire
Via GlobeNewswire
TechMediaBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Enters Robotics And AI Biopharma Partnership With Oncotelic Therapeutics (OTCQB: OTLC)
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026
Via Investor Brand Network
Topics Artificial Intelligence Regulatory Compliance
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026
Via Investor Brand Network
Topics Artificial Intelligence Regulatory Compliance
News headline image
Growth Stocks: NGTF, AMLM, CSDX, OTLC, ECGI Across Robotics, Precious Metals, MedTech and Blockchain
Via AB Newswire
Topics Economy Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends
Via Investor Brand Network
Topics Intellectual Property
News headline image
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Oncotelic Therapeutcs Inc publicly traded?
Yes, Oncotelic Therapeutcs Inc is publicly traded.
What exchange does Oncotelic Therapeutcs Inc trade on?
Oncotelic Therapeutcs Inc trades on the OTC Traded
What is the ticker symbol for Oncotelic Therapeutcs Inc?
The ticker symbol for Oncotelic Therapeutcs Inc is OTLC on the OTC Traded
What is the current price of Oncotelic Therapeutcs Inc?
The current price of Oncotelic Therapeutcs Inc is 0.0370
When was Oncotelic Therapeutcs Inc last traded?
The last trade of Oncotelic Therapeutcs Inc was at 04/09/26 01:29 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.